Navigation Links
Nexavar Data to be Presented at 46th American Society of Clinical Oncology Annual Meeting
Date:5/20/2010

nd individual investigators as a single agent or as a combination treatment in a wide range of cancers, including lung, thyroid, breast, ovarian, and colorectal cancer and as an adjuvant therapy for liver and kidney cancer. 

Important Safety Considerations For Patients Taking Nexavar

Based on the currently approved U.S. package insert for the treatment of patients with unresectable hepatocellular carcinoma and advanced kidney cancer, hypertension may occur early in the course of therapy and blood pressure should be monitored weekly during the first six weeks of therapy and treated as needed.  In HCC patients, bleeding with a fatal outcome from any site was reported in 2.4% for Nexavar and 4% in placebo.  The incidence of treatment-emergent cardiac ischemia/infarction was 2.7% for Nexavar vs. 1.3% for placebo.  In RCC patients, incidence of bleeding regardless of causality was 15% for Nexavar vs. 8% for placebo and the incidence of treatment-emergent cardiac ischemia/infarction was 2.9% for Nexavar vs. 0.4% for placebo.  Most common adverse events >/=20% related to Nexavar for both HCC and RCC were fatigue, weight loss, rash/desquamation, hand-foot skin reaction, alopecia, diarrhea, nausea, and abdominal pain.  Grade 3/4 adverse events in HCC and RCC patients, respectively, were 45% for Nexavar vs. 32% for placebo and 38% for Nexavar and 28% for placebo.  Women of child-bearing potential should be advised to avoid becoming pregnant and advised against breast-feeding.  In cases of any severe or persistent side effects, temporary treatment interruption, dose modification or permanent discontinuation should be considered.

For information about Nexavar including U.S. Nexavar prescribing information, visit

SOURCE Bayer HealthCare Pharmaceuticals, Inc.; Onyx Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. Onyx Pharmaceuticals Announces a Teleconference and Webcast to Provide an Update on Nexavar and Report Full Year 2007 Financial Results
2. Bayer and Onyx Announce Nexavar Data Presentations at 44th American Society of Clinical Oncology Annual Meeting
3. Onyx Pharmaceuticals Announces a Teleconference and Webcast to Provide an Update on Nexavar
4. Bayer and Onyx Announce Nexavar Data Presentations at 45th American Society of Clinical Oncology Annual Meeting
5. Three Studies by Independent Scientists Highlighting Pressure Cycling Technology (PCT) to be Presented this Week at the British Mass Spectrometry Societys 29th Annual Meeting
6. Survival Data Presented From Phase II Study of Investigational Drug ZD4054 in Hormone-Resistant Prostate Cancer Patients
7. New Data Presented on Immunocytokine Fusion Protein Further Supports Broad Anti-Cancer Potential Of Peregrines Anti-PS Technology Platform
8. Results of Colon Cancer Study Utilizing Pressure Cycling Technology (PCT) Presented at the American College of Gastroenterology Annual Scientific Meeting
9. Kuvan, Naglazyme and Aldurazyme Data to Be Presented at the 57th Annual Meeting of the American Society of Human Genetics
10. Micromet Data Presented at the International AACR-NCI-EORTC Conference Support the Development of Adecatumumab (MT201) in Earlier Stage Cancer Disease Settings
11. Three PDX (Pralatrexate) Studies Presented at the 2007 AACR-NCI-EORTC Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/20/2014)... 20, 2014 Not long ago, it ... should be performed late in the development cycle – ... current regulatory trends suggest that, like many things GxP, ... In recent years, multiple drug sponsors have been required ... specific questions during phase I/II. It’s not only clinical ...
(Date:8/20/2014)... 20, 2014 GraphDB™ 6.0 ... including improvements to the enterprise replication cluster, faster ... Lucene, SOLR and Elasticsearch. This release happens to ... performance triplestore – GraphDB™ was formerly known as ... the only mature enterprise resilient RDF triplestore will ...
(Date:8/19/2014)... , Aug. 19, 2014 A Geisinger ... been nominated for a Centers for Disease Control and ... a major public health concern. Joseph ... is one of a team of researchers nominated for ... C. Shepard Science Award for Data Methods and Study ...
(Date:8/19/2014)... 2014 XenoTech announces an exclusive ... metabolite production from bioactive small molecules. Based ... technology enables convenient and timely assessment of critical ... Vice President of Commercial Operations, Christian Darabant, “the ... risk can be measured directly by comparison with ...
Breaking Biology Technology:Are Extractable and Leachables going Phase-Appropriate? New Webinar Hosted by Xtalks 2Ontotext Improves Its RDF Triplestore, GraphDB™ 6.0: Enterprise Resilience, Faster Loading Speeds and Connectors to Full-Text Search Engines Top the List of Enhancements 2Ontotext Improves Its RDF Triplestore, GraphDB™ 6.0: Enterprise Resilience, Faster Loading Speeds and Connectors to Full-Text Search Engines Top the List of Enhancements 3Ontotext Improves Its RDF Triplestore, GraphDB™ 6.0: Enterprise Resilience, Faster Loading Speeds and Connectors to Full-Text Search Engines Top the List of Enhancements 4Geisinger investigator nominated for federal award 2Geisinger investigator nominated for federal award 3Beyond Metabolite Identification, Testable Quantities Now Offered by XenoTech 2Beyond Metabolite Identification, Testable Quantities Now Offered by XenoTech 3
... pace for healthcare in the Philadelphia suburbs, with unique new capabilities ... ... technologies, IRVINE, Calif., Jan. 10 ... Pulse CO-Oximetry and,Read-Through-Motion & Low Perfusion Pulse Oximetry, have announced the,completion ...
... Alerts for key stocks., Seven Summits Strategic Investments, ... (Note: You may have to copy this link,into your ... Alerts cover the following stocks: Exxon Mobil Corp.,(NYSE: ... MER ), DryShips, Inc. (Nasdaq:,DRYS), Computer Sciences Corp. (NYSE: ...
... 10 Transgene,(Euronext Paris: FR0005175080) announces promising preliminary ... vaccine TG4010,(MVA-MUC1-IL2) as an adjunct to first line ... (NSCLC)., This on-going trial is a randomized, ... efficacy of TG4010 in combination with cisplatin and,gemcitabine ...
Cached Biology Technology:Abington Memorial Hospital Completes System-Wide Conversion to Masimo SET Pulse Oximetry Technology 2Abington Memorial Hospital Completes System-Wide Conversion to Masimo SET Pulse Oximetry Technology 3Abington Memorial Hospital Completes System-Wide Conversion to Masimo SET Pulse Oximetry Technology 4Seven Summits Research Releases Alerts on XOM, MER, DRYS, CSC, and PDLI 2Seven Summits Research Releases Alerts on XOM, MER, DRYS, CSC, and PDLI 3Transgene's Therapeutic Vaccine TG4010 Shows Promising Preliminary Phase IIb Data in Advanced Non-Small Cell Lung Cancer 2Transgene's Therapeutic Vaccine TG4010 Shows Promising Preliminary Phase IIb Data in Advanced Non-Small Cell Lung Cancer 3
(Date:8/19/2014)... It,s not a monkey. It,s not a lemur. It,s ... Meet the Philippine tarsier: a tiny, adorable and downright "cool" ... animals that Americans are familiar with," said Rafe Brown, curator-in-charge ... giant eyes and ears; an extremely cute, furry body; a ... interesting expanded fingers and toe tips that look a bit ...
(Date:8/19/2014)... born with neonatal abstinence syndrome (NAS) secondary to ... going through withdrawal than others, but the underlying ... epigenetic (when genes are turned on or off) ... researchers at Boston University School of Medicine (BUSM) ... of its kind study to identify some of ...
(Date:8/19/2014)... ever had a glass of fizzy soda knows that ... in a finding with wide industrial applications, Princeton researchers ... down into the liquid as well. , "It is ... we were surprised, and fascinated, to discover that when ... injected tiny oil droplets into the water," said Howard ...
Breaking Biology News(10 mins):Philippine tarsier gets boost from Kansas research, and genetic proof of a new variety 2Philippine tarsier gets boost from Kansas research, and genetic proof of a new variety 3In-utero methadone, Subutex exposure could alter gene expression, cause severe Neonatal Abstience Syndrome 2Bubbling down: Discovery suggests surprising uses for common bubbles 2Bubbling down: Discovery suggests surprising uses for common bubbles 3
... bacteria, and like any hardworking homeowner, they have developed ... Berkeley, biologists have found. , In a study of ... its roots, UC Berkeley researchers have shown that the ... than they do to the slackers. Root nodules - ...
... The risk of human bird flu infection is small in Australia ... according to bird medicine specialist Dr Bob Doneley. , "The ... neighbours birds are so infinitesimally small," UQ School of Veterinary Science ... have a light plane hit by a meteor and fall on ...
... now have access to one of the most advanced microscopes ... Facility, opened this fall, is a combination of an atomic ... commercial machine of its kind. , The atomic force microscope ... confocal microscope system by Olympus America Inc. Integration of the ...
Cached Biology News:Plants, too, have ways to manage freeloaders 2Plants, too, have ways to manage freeloaders 3Plants, too, have ways to manage freeloaders 4Expert dispels bird flu paranoia 2
... Trap Time of Flight Mass Analyzer for superior sensitivity, mass accuracy, ... - 25,000 m/z, * Precursor ion selection range: 150 - 4000 ... 5 ppm with internal reference, * Dynamic range: 4 orders of ... ...
... pYD1 Yeast Display Vector is specifically designed ... the surface of Saccharomyces cerevisiae. Displayed proteins ... interact with known or putative ligands. pYD1 ... consists of two domains, Aga1 and Aga2, ...
... Oncostatin M (OSM) is a pleiotropic ... and Kaposis sarcoma cells. OSM inhibits the ... lines, simulates fibroblast, smooth muscle and Kaposis ... cells and low density lipoprotein receptor expression ...
Mouse polyclonal antibody to BTAF1 - BTAF1 RNA polymerase II, B-TFIID transcription factor-associated, 170kDa (Mot1 homolog, S. cerevisiae)...
Biology Products: